ACM
ALNY icon

Asymmetry Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Asymmetry Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-8,754
Closed -$818K – 32
2019
Q1 		$818K Buy
+8,754
New +$732K 1.37% 19

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Asymmetry Capital Management's ALNY Position: Q2 2019 in Review

Asymmetry Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2019, closing a stake of 8,754 shares — an estimated $818K sold.

Asymmetry Capital Management first reported a position in ALNY in Q1 2019 and held it in 1 quarter. The position peaked at $818K in Q1 2019. 290 funds tracked by Wall St. Rank hold ALNY as of Q2 2019.

  • Asymmetry Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Asymmetry Capital Management sold 8,754 Alnylam Pharmaceuticals shares in Q2 2019, an estimated $818K.
  • Asymmetry Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Asymmetry Capital Management's Alnylam Pharmaceuticals position peaked at $818K in Q1 2019.
  • 290 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2019.

Based on Asymmetry Capital Management's 13F filing for Q2 2019, filed 7 Aug 2019.